Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2024-04-11 SenzaGen NOTICE OF ANNUAL GENERAL MEETING OF SENZAGEN AB (Publ) Pressreleaser Ladda ner | Visa Stäng
2024-04-11 SenzaGen Kallelse till årsstämma i SenzaGen AB (Publ) Pressreleaser Ladda ner | Visa Stäng
2024-03-25 SenzaGen SenzaGen’s chemical industry orders continue to increase Pressreleaser Ladda ner | Visa Stäng
2024-03-25 SenzaGen SenzaGens orderingång från kemikalieindustrin fortsätter att öka Pressreleaser Ladda ner | Visa Stäng
2024-03-22 SenzaGen SenzaGen publicerar årsredovisningen för 2023 Rapporter Ladda ner | Visa Stäng
2024-03-22 SenzaGen SenzaGen’s Annual Report 2023 published Rapporter Ladda ner | Visa Stäng
2024-03-06 SenzaGen SenzaGen presenterar och anordnar paneldebatt på SOT Annual Meeting & ToxExpo 2024 Pressreleaser Ladda ner | Visa Stäng
2024-03-06 SenzaGen SenzaGen presents and hosts a panel discussion at the SOT Annual Meeting & ToxExpo 2024 Pressreleaser Ladda ner | Visa Stäng
2024-02-20 Penser Access by Carnegie Penser Access by Carnegie: Intervju med SenzaGen - Carnegie Investment Bank - 20 feb 2024 Pressreleaser Visa Stäng
2024-02-15 Penser Access by Carnegie Penser Access by Carnegie: SenzaGen - Bra position in i 2024 Pressreleaser Visa Stäng
2024-02-15 Redeye Redeye: SenzaGen H2 - Continued growth and aligned with our expectations Pressreleaser Ladda ner | Visa Stäng
2024-02-14 SenzaGen SenzaGen’s 2023 Year-End Report: Company approaching breakeven with SEK 50 million in sales Rapporter Ladda ner | Visa Stäng
2024-02-14 SenzaGen SenzaGens bokslutskommuniké 2023: Bolaget närmar sig break-even med en omsättning på 50 miljoner kronor Rapporter Ladda ner | Visa Stäng
2024-02-07 SenzaGen Invitation to the presentation of SenzaGen’s year-end report 2023 on Feb 14 at 10.00 CET Pressreleaser Ladda ner | Visa Stäng
2024-02-07 SenzaGen Inbjudan till presentation av SenzaGens bokslutskommuniké 2023 den 14 februari kl 10.00 Pressreleaser Ladda ner | Visa Stäng
2024-01-10 SenzaGen SenzaGen får uppföljningsorder värd 1,5 MSEK för GARD®skin-tester till kemikalieindustrin Pressreleaser Ladda ner | Visa Stäng
2024-01-10 SenzaGen SenzaGen receives a follow-up order worth 1.5 million SEK for GARD®skin for the chemical industry Pressreleaser Ladda ner | Visa Stäng
2023-12-18 SenzaGen SenzaGen får order på 1,7 MSEK från ny världsledande kund inom biotech-industrin Pressreleaser Ladda ner | Visa Stäng
2023-12-18 SenzaGen SenzaGen secures SEK 1.7m order from a new global biotech industry leader Pressreleaser Ladda ner | Visa Stäng
2023-11-29 SenzaGen SenzaGen byter likviditetsgarant till Carnegie Pressreleaser Ladda ner | Visa Stäng
2023-11-29 SenzaGen SenzaGen changes its market maker to Carnegie Pressreleaser Ladda ner | Visa Stäng
2023-11-08 SenzaGen SenzaGen är ett av Sveriges snabbast växande teknikbolag Pressreleaser Ladda ner | Visa Stäng
2023-11-08 SenzaGen SenzaGen ranked one of Sweden's fastest-growing technology companies Pressreleaser Ladda ner | Visa Stäng
2023-10-26 SenzaGen SenzaGen secures strategically important order from new customer, a world leader in fast-moving consumer goods (FMCG) Pressreleaser Ladda ner | Visa Stäng
2023-10-26 SenzaGen SenzaGen säkrar strategiskt viktig order från ny världsledande kund inom FMCG (dagligvaror) Pressreleaser Ladda ner | Visa Stäng
2023-10-25 SenzaGen Continued growth and expanded customer base for SenzaGen during the third quarter Pressreleaser Ladda ner | Visa Stäng
2023-10-25 SenzaGen Fortsatt tillväxt och breddad kundbas för SenzaGen under tredje kvartalet Pressreleaser Ladda ner | Visa Stäng
2023-10-18 SenzaGen SenzaGen presenterar på BioStock Life Science Summit den 26 oktober Pressreleaser Visa Stäng
2023-09-28 SenzaGen SenzaGen continues to collaborate with RIFM in non-animal photosensitization and fragrance safety – receives a new grant worth SEK 1.6m Pressreleaser Ladda ner | Visa Stäng
2023-09-28 SenzaGen SenzaGen fortsätter att samarbeta med RIFM inom djurfri fotosensibilisering och doftsäkerhet – får nytt uppdrag värt 1,6 MSEK Pressreleaser Ladda ner | Visa Stäng
2023-08-25 Penser Access Penser Access: På väg mot kassaflödesneutralitet - SenzaGen Pressreleaser Visa Stäng
2023-08-25 Redeye Redeye: SenzaGen H1 2023 - Increased customer base Pressreleaser Ladda ner | Visa Stäng
2023-08-24 SenzaGen SenzaGens halvårsrapport 2023: Fortsatt tillväxt, förbättrad bruttomarginal och minskad förlust Rapporter Ladda ner | Visa Stäng
2023-08-24 SenzaGen SenzaGen’s 2023 Half-Year Report: Continued growth, improved gross margin and lower loss Rapporter Ladda ner | Visa Stäng
2023-07-07 SenzaGen SenzaGen stärker marknadsnärvaron genom utökade distributionskanaler Pressreleaser Ladda ner | Visa Stäng
2023-07-07 SenzaGen SenzaGen strengthens its market presence with expanded distribution channels Pressreleaser Ladda ner | Visa Stäng
2023-05-12 Penser Access Penser Access: Intervju med SenzaGen - Erik Penser Bank - 11 maj 2023 Pressreleaser Visa Stäng
2023-05-11 SenzaGen SenzaGen utser likviditetsgarant Pressreleaser Ladda ner | Visa Stäng
2023-05-11 SenzaGen SenzaGen appoints market maker Pressreleaser Ladda ner | Visa Stäng
2023-05-04 SenzaGen Kommuniké från årsstämma i SenzaGen AB den 4 maj 2023 Pressreleaser Ladda ner | Visa Stäng
2023-05-04 SenzaGen Report from AGM of SenzaGen AB on 4 May 2023 Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 4 May 2023 | SenzaGen

Report from AGM of SenzaGen AB on 4 May 2023

The Annual General Meeting (AGM) of SenzaGen held on today’s date, 4 May 2023 in Lund, resolved to pass all proposals presented by the board and shareholders.

Adoption of income statement and balance sheet
The AGM adopted the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for 2022.

Appropriation of earnings
The AGM resolved that no dividend be paid to shareholders and that the earnings at the disposal of the AGM be carried forward.

Discharge from liability
The AGM discharged the board directors and CEO from liability for the 2022 financial year.

Election of directors and auditors and their fees
The AGM resolved that the board shall consist of five directors and no alternates. Carl Borrebaeck, Ian Kimber, Anki Malmborg Hager, Paula Zeilon and Paul Yianni were re-elected as directors. Carl Borrebaeck was also re-elected as board chairman. Authorized Public Accountant Mats-Åke Andersson was elected as auditor, with Authorized Public Accountant Martin Gustafsson as deputy auditor.

The AGM resolved to set directors’ fees at SEK 1,200,000 in total, with SEK 200,000 for each non-employee director and SEK 400,000 for the board chairman. Auditor’s fees shall be payable on the basis of approved invoices.

Remuneration policies for senior executives
The AGM resolved, as proposed by the board, to adopt remuneration policies for senior executives.

Authorization for the board to resolve to issue new shares
The AGM resolved, as proposed by the board, to authorize the board, for the period until the next AGM, with the shareholders’ preemptive rights waived, on one or more occasions, to decide to issue new shares, stock options or convertibles. The total number of shares that may be issued or, if convertibles or stock options are issued, added following conversion or exercise of rights under the authorization is limited to 20 percent of the number of shares outstanding on the date of the notice of the AGM. As a result, the maximum number of shares that may be issued is 6,047,081, and the Company’s share capital may be increased by a maximum of SEK 302,354.05.

The purpose of the authorization is to enable the board to raise working capital for the Company, and/or bring in new owners of strategic significance to the Company, and/or acquire other companies or businesses.

Directed issue of a maximum of 1,015,000 stock options
The AGM resolved, as proposed by the board, to issue a maximum of 1,015,000 stock options, as a result of which the Company’s share capital may increase by a maximum of SEK 50,750. The stock options will entitle the holder to subscribe for new shares in the Company.

With the shareholders’ preemptive rights waived, employees of the Company and the Group shall be entitled to subscribe for the stock options as follows:

  • The Group CEO will be offered to subscribe for a maximum of 200,000 options.
  • Members of Group Management and key personnel comprising up to eight positions will each be offered to subscribe for a maximum of 50,000 options, altogether comprising a maximum of 450,000 options.
  • Consultants within Group Management, comprising two individuals, will each be offered to subscribe for a maximum of 25,000 options, altogether comprising a maximum of 50,000 options.
  • Other employees and consultants considered key personnel in the Group, comprising up to twenty-three individuals, will be offered to subscribe for between 10,000 and 25,000 options each, altogether comprising a maximum of 315,000 stock options.

The subscriber is entitled to subscribe for stock options free of charge. Given that the stock options are issued free of charge, the Company estimates that fringe benefits and social security expenses will be incurred for the participant and the Company as a result of the option plan. The total expenses, including other expenses in the form of fees to external advisers and expenses for the administration of the plan, are estimated at around SEK 100,000 over the program’s term and the cost of social security expenses is estimated at SEK 631,991.

The market value of the option shall be calculated using the Black-Scholes pricing model subject to barrier conditions to calculate the Company’s social security expenses. The valuation of the options shall be performed by an independent valuation institute or auditing firm.

Each stock option entitles the holder to subscribe for one new share in the Company in exchange for cash payment, provided that the barrier conditions have been met, during the period from 1 June 2026 to 30 September 2026 or the earlier date set out in the option rules.

Payment for shares subscribed for by exercising stock options shall be made in cash at an exercise price of 100% of the average of the listed volume-weighted price paid for each trading day as per Nasdaq First North Growth Markets’ official price list for shares in the Company during the period from 19 April 2023 to 3 May 2023.

For each individual participant in the stock option plan, 80 percent of all allotted stock options are subject to barrier conditions, and these 80 percent of the stock options can only be exercised to subscribe for shares once the volume-weighted price paid measured per trading day as per the Nasdaq First North Growth Market’s official price list for shares is higher than the respective barrier level.

The barrier levels are calculated as a percentage of the average volume-weighted price as per the Nasdaq First North Growth Market’s official price list for shares in the Company during the period from 19 April 2023 to 3 May 2023 ( “the Barrier Price” ).

The barrier levels shall consist of two barriers, with the first barrier accounting for 25 percent ( “Barrier 1” ) and the second barrier accounting for 55 percent ( “Barrier 2” ) of all the stock options allotted to participants, in accordance with what is set out below.

  • Barrier 1: 25 percent of the stock options are subject to Barrier 1 and the barrier is calculated at 158 percent of the Barrier Price.
  • Barrier 2: 55 percent of the stock options are subject to Barrier 2 and the barrier is calculated at 300 percent of the Barrier Price.

New shares subscribed for by exercising stock options entitle the holder to dividends for the first time on the dividend record date most immediately following the date the new share issue was registered with the Swedish Companies Registration Office and Euroclear Sweden AB.

For detailed rules regarding the resolution passed at the AGM, please see the AGM notice available at the Company’s website, www.senzagen.com .

2023-05-04 Penser Access Penser Access: Giftfri tillväxt - SenzaGen Pressreleaser Visa Stäng
2023-04-26 SenzaGen Uthållig och stark försäljningsutveckling för SenzaGen under årets första kvartal Pressreleaser Ladda ner | Visa Stäng
2023-04-26 SenzaGen Consistent and strong sales growth for SenzaGen in Q1 2023 Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

15 May 2024 | Årsstämma 2023
15 May 2024 | Kvartalsrapport 2024-Q1
16 May 2024 | Årligutdelning
15 Aug 2024 | Kvartalsrapport 2024-Q2
8 Nov 2024 | Kvartalsrapport 2024-Q3